Myriad Genetics Stock
Myriad Genetics Stock
Myriad Genetics dominated the market today, gaining €0.16 (3.610%).
Currently there is a rather positive sentiment for Myriad Genetics with 3 Buy predictions and 0 Sell predictions.
As a result the target price of 7 € shows a very positive potential of 51.61% compared to the current price of 4.62 € for Myriad Genetics.
Criterium "EBIT growth" is seen as the biggest plus for Myriad Genetics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Myriad Genetics in the next few years
Pros
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | 3.610% | -7.568% | -6.972% | 30.424% | -12.887% | -76.915% | -82.740% |
| Healthequity Inc. | -3.310% | 6.707% | 11.465% | 2.941% | 12.179% | 49.573% | 40.585% |
| Bruker Corp. | -3.550% | 2.445% | 3.417% | 61.758% | 33.562% | -13.524% | - |
| Omnicell Inc. | -10.670% | -10.674% | -10.169% | 17.778% | -18.041% | -44.211% | -73.051% |
Comments
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
